Abnormal glucose metabolism in the brain is now recognized as an early biomarker of AD and may also contribute to its pathogenesis, affecting Aβ and Tau metabolism, mitochondrial function, cellular signaling, and neuronal plasticity [13]. The gene discussed is MAPT; the disease is Alzheimer disease.